“We continue to win large hospital evaluations and this IDN contract is another major milestone for Senzime in the US market. We estimate the full installation at this hospital system to reach close to 300 TetraGraph systems when fully deployed. The supply contract is a confirmation of our leading product offering, team, and commitment to patient safety. Senzime is perceived as the trusted, long-term vendor of choice, with the capabilities of effectively implementing and supporting large scale implementations. The first TetraGraph and sensor shipments under this contract have already been made”, comments Philip Siberg, CEO of Senzime.

The TetraGraph is the first portable electromyography (EMG)-based neuromuscular monitor on the market that is clinically validated and meets new clinical guidelines published by ASA (American Society of Anesthesiologists) and ESAIC (European Society of Anaesthesiology and Intensive Care). Since its market introduction in 2019, the TetraGraph has been installed at hundreds of leading hospitals across the globe.
 
The TetraGraph system is used during surgery to monitor the patient’s level of neuromuscular blockade accurately. This helps anaesthesiologists secure the right dose of neuromuscular blocking drugs and indicate when it is safe to allow patients to breathe on their own, and thereby avoid serious complications and increase healthcare efficiency.